Presentation is loading. Please wait.

Presentation is loading. Please wait.

PRIMARY & SECONDARY ANTIBODY DEFICIENCY. ANTIBODIES & IMMUNOGLOBULINS.

Similar presentations


Presentation on theme: "PRIMARY & SECONDARY ANTIBODY DEFICIENCY. ANTIBODIES & IMMUNOGLOBULINS."— Presentation transcript:

1 PRIMARY & SECONDARY ANTIBODY DEFICIENCY

2 ANTIBODIES & IMMUNOGLOBULINS

3 PRIMARY ANTIBODY DEFICIENCY The European internet-based patient and research database for primary immunodeficiencies: results Gathman et al., Clin Exp Immunol (2009); 157 Suppl 1: 3-11.

4

5 Brit Med J (1989); 298: 516-7

6 THERAPEUTIC IMMUNOGLOBULIN 1970s - IMIg 1980s - IVIg 1990s - IVIg, SCIg 2000s - product safety - infusion rates / concentration - immunoglobulin retrieval

7 REPLACEMENT THERAPY

8 TREATMENT OUTCOMES Wood et al. Clin Exp Immunol (2007); 149:

9 EFFICACY & ADVERSITY Immunoglobulin Excipients Soluble CD4/ CD8/ HLA Cytokines Clin Exp Immunol (2004); 136: 111-3

10 IVIg & SCIg ESID Register 2009

11 HOME THERAPY

12 2008 and 2011

13 SAME OLD SAME OLD Core of PID management No alternatives Lifelong requirement (usually) Effective (bacterial infection, antibiotic usage, QoL, hospitalisation, life expectancy) Dose requirement  in: - frequent breakthrough infections - chronic inflammation / tissue damage - poor prognosis disease variants

14 WHAT’S NEW? The three Rs: Reorganisation Reclassification Aarrrgh - ongoing uncertainties over dosing / target levels

15 DOSE? Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Orange JS et al. Clinical Immunology (2010); 137: 21-30

16 DOSE: INDIVIDUALISATION ‘The goal of replacement therapy should be to improve clinical outcome and not to reach a particular IgG trough level.’ J Allergy Clin Immunol (2010);125:

17 DOSE: INDIVIDUALISATION ‘….individualizing the dosage….is preferable to using mean pharmacokinetic parameters.’ Clin Immunol (2011);139:133-41

18 RECLASSIFICATION Specific Antibody Deficiency  Kawasaki Disease  ‘Other’ Section

19 REORGANISATION

20 PRIMARY ANTIBODY DEFICIENCY DISORDERS

21 SPECIFIC DISORDERS Thymoma with immunodeficiency (Good’s Syndrome) Combined immunodeficiencies requiring haemopoietic stem cell transplantation (HSCT) Specific antibody deficiency (SAD) Transient hypogammaglobulinaemia of infancy (THI)

22 SPECIFIC DISORDERS DISORDER RECOMMENDATION / REQUIREMENT GOOD’SProfound B cell depletion / significant antibody deficiency HSCTDuration based on B cell reconstitution post-transplantation SADRobust application of selection criteria THIDefine planned duration of therapy prior to initiation (GRADE C, LEVEL III)

23 SUMMARY: PID

24 SECONDARY ANTIBODY DEFICIENCY Malignant disease Drugs Protein-losing states Infection (cause & effect) Systemic disease Iatrogenic causes Chromosomal abnormalities

25 WHAT’S NEW? Secondary Antibody Deficiency  Revision / collation into a single indication + review outcomes (infection / hospitalisation) + dosing (minimum IgG trough 6 g/L)

26 RECOMMENDATIONS Irreversible hypo-  Hypo-  associated with CLL/NHL/MM etc. and

27 GUIDELINES ‘Systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances’ Evidence-based use Consistency of care Access to safe, high quality products Security of supply Utilising scarce resource

28

29 OUTCOMES COMPLICATIONS PROGRESSION OF COMPLICATIONS QUALITY OF LIFE WORKING CAPACITY LIFE EXPECTANCY OPTIMISED GROWTH / DEVELOPMENT

30


Download ppt "PRIMARY & SECONDARY ANTIBODY DEFICIENCY. ANTIBODIES & IMMUNOGLOBULINS."

Similar presentations


Ads by Google